Rocephin and Infusion site swelling - a phase IV clinical study of FDA data

Summary:

Infusion site swelling is reported as a side effect among people who take Rocephin (ceftriaxone sodium), especially for people who are female, 60+ old, also take Lasix, and have Immunodeficiency common variable.

The phase IV clinical study analyzes which people have Infusion site swelling when taking Rocephin. It is created by eHealthMe based on reports of 15,458 people who have side effects when taking Rocephin from the FDA, and is updated regularly.

What is Rocephin?

Rocephin has active ingredients of ceftriaxone sodium. It is often used in infection. eHealthMe is studying from 15,665 Rocephin users. Check the latest studies of Rocephin.

What is Infusion site swelling?

Infusion site swelling is found to be associated with 578 drugs and 360 conditions by eHealthMe. Check the latest studies of Infusion site swelling.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

15,458 people reported to have side effects when taking Rocephin.
Among them, 11 people (0.07%) have Infusion site swelling.

Could Rocephin cause Infusion site swelling?

Among these 11 people:

What is the gender of people who have Infusion site swelling when taking Rocephin? *

female: 81.82 %
male: 18.18 %

What is the age of people who have Infusion site swelling when taking Rocephin? *

What are other drugs people take besides Rocephin? *

What are other side effects people have besides Infusion site swelling? *

Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 9 people, 81.82%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 9 people, 81.82%
Sinusitis (inflammation of sinus): 9 people, 81.82%
Fall: 9 people, 81.82%
Hypotension (abnormally low blood pressure): 9 people, 81.82%
Infusion Site Discomfort: 9 people, 81.82%
Cardiac Disorder: 8 people, 72.73%
Cough: 8 people, 72.73%
Spinal Disorder (disease of spine a back bone): 8 people, 72.73%
Fainting (loss of consciousness and postural tone): 8 people, 72.73%

What are the existing conditions these people have? *

Immunodeficiency Common Variable: 9 people, 81.82%
Hypergammaglobulinaemia (elevated levels of gamma globulin): 6 people, 54.55%
Immune System Disorder: 5 people, 45.45%
Neuropathy Peripheral (surface nerve damage): 3 people, 27.27%
Ill-Defined Disorder: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Rocephin and have Infusion site swelling?

- Check whether Infusion site swelling is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rocephin:

Rocephin (15,665 reports)

Browse all side effects of Rocephin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Infusion site swelling:

Infusion site swelling (578 drugs)

Browse all the conditions that are associated with Infusion site swelling:

Infusion site swelling (360 conditions)

Related publications that referenced our studies

Agrawal SR, Rajput A, Jain AP, "Leukocytoclastic vasculitis and acute allergic interstitial nephritis following ceftriaxone exposure", Journal of pharmacology & pharmacotherapeutics, 2014 Jan .
Agrawal SR, Rajput A, Jain AP, "Leukocytoclastic vasculitis and acute allergic interstitial nephritis following ceftriaxone exposure", Journal of pharmacology & pharmacotherapeutics, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on ceftriaxone sodium (the active ingredients of Rocephin) and Rocephin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.